Anavex Life Sciences Corp
AVXL12.130USD
-0.610-4.79%
終値 07/25, 16:00（ET）15分遅れの株価
1.04B時価総額
損失額直近12ヶ月PER
詳細情報 Anavex Life Sciences Corp 企業名
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
企業情報
企業コードAVXL
会社名Anavex Life Sciences Corp
上場日Apr 13, 2006
設立日2004
最高経営責任者「CEO」Dr. Christopher U. Missling, Ph.D.
従業員数42
証券種類Ordinary Share
決算期末Apr 13
本社所在地630 5Th Avenue
都市NEW YORK
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号10111
電話番号18446893939
ウェブサイトhttps://www.anavex.com
企業コードAVXL
上場日Apr 13, 2006
設立日2004
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.47M
--
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Steffen Thomas, Ph.D.
Dr. Steffen Thomas, Ph.D.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.47M
--
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Fri, May 16
更新時刻: Fri, May 16
株主統計
種類
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
7.00%
The Vanguard Group, Inc.
5.72%
State Street Global Advisors (US)
3.77%
Geode Capital Management, L.L.C.
2.30%
Missling (Christopher U)
1.72%
Other
79.49%
株主統計
株主統計
比率
BlackRock Institutional Trust Company, N.A.
7.00%
The Vanguard Group, Inc.
5.72%
State Street Global Advisors (US)
3.77%
Geode Capital Management, L.L.C.
2.30%
Missling (Christopher U)
1.72%
Other
79.49%
種類
株主統計
比率
Investment Advisor
22.93%
Investment Advisor/Hedge Fund
9.72%
Individual Investor
3.33%
Hedge Fund
2.49%
Research Firm
1.58%
Bank and Trust
0.78%
Pension Fund
0.24%
Insurance Company
0.03%
Other
58.91%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
353
35.09M
41.11%
+424.70K
2025Q1
362
35.10M
41.13%
+789.16K
2024Q4
351
32.45M
38.14%
-89.26K
2024Q3
337
29.80M
35.14%
-2.92M
2024Q2
337
29.64M
35.02%
-6.78M
2024Q1
332
34.88M
42.48%
+4.38M
2023Q4
335
28.85M
35.15%
-996.59K
2023Q3
331
28.07M
34.33%
-2.23M
2023Q2
335
28.30M
35.04%
-4.91M
2023Q1
340
29.94M
37.61%
-3.19M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
BlackRock Institutional Trust Company, N.A.
5.98M
7%
+20.29K
+0.34%
Mar 31, 2025
The Vanguard Group, Inc.
4.88M
5.72%
+202.97K
+4.34%
Mar 31, 2025
State Street Global Advisors (US)
3.21M
3.77%
+802.33K
+33.26%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.96M
2.3%
+89.89K
+4.79%
Mar 31, 2025
Missling (Christopher U)
1.47M
1.72%
--
--
Apr 25, 2025
Two Sigma Investments, LP
1.37M
1.6%
+100.80K
+7.95%
Mar 31, 2025
Skarpelos (Athanasios)
1.31M
1.53%
--
--
Apr 25, 2025
Northwest Asset Management
1.00M
1.17%
+87.30K
+9.56%
Mar 31, 2025
Susquehanna International Group, LLP
787.10K
0.92%
-347.64K
-30.64%
Mar 31, 2025
Northern Trust Investments, Inc.
674.75K
0.79%
-26.63K
-3.80%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sun, Jul 6
更新時刻: Sun, Jul 6
銘柄名
比率
Invesco Dorsey Wright Healthcare Momentum ETF
1.85%
iShares Neuroscience and Healthcare ETF
1.48%
ALPS Medical Breakthroughs ETF
0.54%
Invesco Dorsey Wright SmallCap Momentum ETF
0.28%
SPDR S&P Biotech ETF
0.22%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Vanguard US Momentum Factor ETF
0.12%
iShares Micro-Cap ETF
0.12%
ProShares Ultra Nasdaq Biotechnology
0.09%
iShares Biotechnology ETF
0.07%
詳細を見る
Invesco Dorsey Wright Healthcare Momentum ETF
比率1.85%
iShares Neuroscience and Healthcare ETF
比率1.48%
ALPS Medical Breakthroughs ETF
比率0.54%
Invesco Dorsey Wright SmallCap Momentum ETF
比率0.28%
SPDR S&P Biotech ETF
比率0.22%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.14%
Vanguard US Momentum Factor ETF
比率0.12%
iShares Micro-Cap ETF
比率0.12%
ProShares Ultra Nasdaq Biotechnology
比率0.09%
iShares Biotechnology ETF
比率0.07%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
